Abstract: A process and a system are disclosed for determining if a combination of a set of chemical compounds has either a synergistic, additive, or antagonistic effect on a disease, e.g., osteoarthritis, or a biological function, e.g., oxidative stress. In one step of the process, for a particular ensemble of molecular pathway models representing the disease or biological function along with the particular set of biomarkers for that disease or biological function, computation is performed to quantify for a particular set of chemical compounds, their effects individually, sequentially, and in combination on the biomarkers. In another step of the process, comparison of these effects is performed to determine if the combinations of the chemical compounds behave synergistically, additively, or antagonistically. The end results are combinations of chemical compounds along with their dosage levels, which synergistically affect disease or biological function of interest.

Abstract: The present disclosure is related to dietary supplements. For example, this disclosure relates to compositions that include, one or more agents that decrease the production of tumor necrosis factor-alpha (TNF-?), decrease the CCL2, and decrease the interleukin-1 beta (IL-1?) responsible for low grade chronic inflammation. In some embodiments, the composition comprises: epicatechin present in an amount of about 0.25% to about 1% w/w of the composition; EGCG present in an amount of about 0.01% to about 0.1% w/w of the composition; lycopene present in an amount of about 1% to about 3% w/w of the composition; quercetin present in an amount of about 0.1% to about 1% w/w of the composition; luteolin present in an amount of about 0.1% to about 1% w/w of the composition; vitamin A present in an amount of about 1% to about 7.5% w/w of the composition; vitamin C present in an amount of about 40% to about 77% w/w of the composition; and vitamin E present in an amount of about 15% to about 40% w/w of the composition.

Abstract: The present disclosure is related to dietary supplements. For example, this disclosure relates to compositions that include, one or more agents that decrease the production of reactive oxygen species (ROS) responsible for oxidative stress, and/or decrease the concentration of ROS. In some embodiments, a composition as provided herein includes epicatechin present in an amount of about 0.1% to about 3% w/w of the composition; vitamin A acid present in an amount of about 1% to about 15% w/w of the composition; vitamin C present in an amount of about 10% to about 80% w/w of the composition; and, vitamin E present in an amount of about 5% to about 60% w/w of the composition. Such compositions are useful for improving oxidative stress by decreasing ROS concentration.

Abstract: The present disclosure is related to dietary supplements. For example, this disclosure relates to compositions that include, for example, one or more agents that decrease the concentration of cyclooxygenase-2, decrease the concentration of transient receptor potential cation channel subfamily V member 1, and/or decrease calcitonin gene-related peptide concentration. In some embodiments, a composition as provided herein includes apigenin present in an amount of about 1% to about 5% w/w of the composition; and hesperidin present in an amount of about 90% to about 99% w/w of the composition. Such compositions are useful for decreasing joint pain and/or inflammation.

Abstract: The present disclosure is related to dietary supplements. For example, this disclosure relates to compositions that include, for example, one or more agents that decrease the concentration of cyclooxygenase-2, decrease the concentration of transient receptor potential cation channel subfamily V member 1, and/or decrease calcitonin gene-related peptide concentration. In some embodiments, a composition as provided herein includes apigenin present in an amount of about 1% to about 5% w/w of the composition; and hesperidin present in an amount of about 90% to about 99% w/w of the composition. Such compositions are useful for decreasing joint pain and/or inflammation.

Abstract: The present disclosure relates to oral compositions that include at least two agents selected from: agents that increase the concentration of glutamate; agents that increase dopamine production; agents that increase the concentration of brain-derived neurotrophic factor (BDNF); NMDA and/or AMPA receptor modulators; and acetylcholinesterase inhibitors. In son embodiments, a composition as provided herein includes D-glutamine present in an amount of about 20% to about 30% w/w of the composition; ginkgolide B present in an amount of about 0.1% to about 0.4% w/w of the composition; phosphatidylserine present in an amount of about 65% to about 80% w/w of the composition; and ascorbic acid present in an amount of about 0.5% to about 2.5% w/w of the composition. Such compositions are useful for improving memory and/or focus.

Abstract: The present disclosure is related to dietary supplements. In some aspects, this disclosure relates to compositions that can include, one or more agents that can increase the synthesis of testosterone, decrease the degradation of testosterone, and/or decrease the oxidative stress. In some embodiments, an agent of the composition includes: a mineral, a carboxylic acid, a flavone, a flavan, a terpinoid, an amino acid, a benzopyran; and a glycoside, and a combination thereof.

Abstract: The present disclosure is related to dietary supplements. For example, this disclosure relates to compositions that include, for example, one or more agents that decrease the concentration of cyclooxygenase-2, decrease the concentration of transient receptor potential cation channel subfamily V member 1, and/or decrease calcitonin gene-related peptide concentration. In some embodiments, a composition as provided herein includes apigenin present in an amount of about 1% to about 5% w/w of the composition; and hesperidin present in an amount of about 90% to about 99% w/w of the composition. Such compositions are useful for decreasing joint pain and/or inflammation.

Abstract: This invention provides a system and method for determining a user's Current System State so as to enhance balance and well-being. A determination process computes force vector values based upon questions and integration of other biological measurements provided via a user interface. These force vector values can include factors such as Transport, Conversion and Storage. A display generator creates a representation of a location of Current System State based upon the force vector values versus a location for Natural System State. The representation defines a three-dimensional volume and the force vector values are arranged in three-dimensions. The user's Natural System State is located at a location in the volume and the Current System State is at another location. The force vector values are each illustratively represented as a discrete color spectrum. Users access the system through a client interconnected through the Internet.

Abstract: A method for integrating molecular pathway models provides a computational architecture to integrate multiple molecular pathway models. The present invention utilizes a number of systems for communicating mathematical models between servers to a main database for the derivation of an integral solution. The present invention provides a method for the creation of a complex model such as a whole cell.

Abstract: A three phase process and system is disclosed for automatically and adaptively filtering and classifying electronic text-based messages, such as e-mail, e-commerce transactions, CGI forms, and optically scanned and textualized written and facsimile messages. In the first phase of processing, the message is subjected to one or more feature extraction methodologies. The output signals from the first phase are then clustered in the second phase of processing using one or more clustering methodologies. The second phase yields a suggested five characteristics of the message: attitude, issue or problem, request, customer type, and author education level. In the third phase, a human operator interface presents the original message along with the proposed properties and allows an operator to correct or tune the properties, and corrections and tuning being fed back into the network of a feature extraction and clustering methodologies.

Abstract: A process and system is disclosed for automatically and adaptively retrieving information from a database and transmitting reply messages based on the content of a received message, such as an e-mail, CGI form, or facsimile document. In one step of the process, an enhanced e-mail editor user interface is employed to display the original message, the system's adaptive analysis results, and the automatically generated reply message so that a user may review the reply, modify the analysis results, and modify the reply message. The process then learns the changes indicated, and updates the adaptive analysis steps which analyze the received messages. In so doing, future reply messages are increasingly more accurate and correct. After the is adaptive algorithms have been sufficiently trained through the user intervention and correction step, the process and system disclosed is capable of fully autonomous reply generation and transmission.

Abstract: A system and method for automating workflow related to the reception, review, distribution, and disposition of client contact through electronic communications. All types of received contact messages are converted to e-mail messages and automatically processed using natural language processing to generate one or more replies. The original message and the reply(ies) are distributed to one or more workflow automation databases, such as customer care databases, direct mail campaign databases, and sales lead databases, for transmission of the reply(ies) to the originator. The method can be realized in a single database or across multiple databases, located on a single computer platform or distributed across multiple networked computer platforms.